Reactivating What Cancer Is Silencing
FDA IND Cleared - Triple-Negative Breast Cancer (TNBC)
TNBC lacks three key therapeutic targets
Estrogen receptor (ER). Progesterone receptor (PR). HER2
8–13 months
Median overall survival for metastatic TNBC.
~50,000 Americans
Diagnosed with TNBC each year.
A different approach to Cancer Biology
Telomir is targeting metal imbalances implicated in epigenetic dysregulation in cancer.
OUR MISSION
Cancer doesn’t just grow.
It silences the genes that should stop it.
Telomir-Zn modulates intracellular metal homeostasis to target iron-dependent epigenetic machinery involved in cancer cell survival.
The Problem
Why TNBC remains difficult to treat
THE PROBLEM
Why TNBC remains difficult to treat
TNBC lacks the receptors that make many breast cancers directly targetable. Chemotherapy remains a backbone of care, and outcomes in metastatic disease remain poor.
Our Approach
Oral epigenetic reprogramming via metal modulation
Our Approach
Oral epigenetic reprogramming via metal modulation
Telomir-Zn modulates intracellular metal homeostasis to target iron-dependent epigenetic machinery involved in cancer survival. By reducing labile iron available to iron-dependent KDM enzymes, Telomir-Zn is designed to alter epigenetic regulation and help reactivate genes that cancer has silenced.
Our Progress
IND Cleared for Phase 1/2 Trial in TNBC
Our Progress
IND Cleared for Phase 1/2 Trial in TNBC
The FDA has cleared the IND for TELO-001, a Phase 1/2 clinical trial evaluating Telomir-Zn in advanced and metastatic TNBC. The study includes dose escalation followed by an efficacy expansion. Site activation is underway.
Telomir-Zn: a first-in-class oral epigenetic therapy for triple-negative breast cancer, designed to reactivate silenced tumor-suppressor genes through metal modulation.